Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAV-121
- Development stage
- Preclinical
- Lead developer
- CSA Biotech
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
CAV-121 is an investigational ceragenin-based therapeutic candidate being developed by CSA Biotech for the treatment of epidermolysis bullosa (EB). Ceragenins are synthetic small molecules designed to mimic the activity of naturally occurring antimicrobial peptides (AMPs), specifically cathelicidins, which are key components of the innate immune system. By mimicking these peptides, CAV-121 is intended to provide broad-spectrum antimicrobial activity and support innate immune biology to address the chronic skin infections and impaired wound healing characteristic of EB. The compound is currently in preclinical or early-stage investigational development and has not yet received regulatory approval.
Beyond the preview
Go deeper on CAV-121.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAV-121.